Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...246247248249250251252253254255256...10661067»
  • ||||||||||  Journal:  Evaluation of COVID-19 Treatments in Iran in Comparison with Local Therapeutic Recommendations: A Population-Level Study on Utilization and Costs of Prescription Drugs. (Pubmed Central) -  Oct 25, 2022   
    The estimated number of patients receiving COVID-19 treatments in some outpatient medicines such as recommended hydroxychloroquine was over 2.2 million...In some fewer specific medicines such as dexamethasone, prednisolone, azithromycin, and naproxen, the estimated number of COVID-19-attributed patients were incomparable with the officially announced number of confirmed cases in the year of study, which could be related to nonconfirmed diagnosed cases, irrational use, or prescribing, or limitations of our data and study...Despite the release of the COVID-19 guideline by Iran MOH, misalignment in the enforcement of decisions was a serious weakness (cases of favipiravir and remdesivir). This weakness led to some economic burden on the health-care system and raised ethical concerns.
  • ||||||||||  prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Journal, IO biomarker:  Rheumatologic Manifestations of Post SARS-CoV-2 Infection: A Case Series. (Pubmed Central) -  Oct 25, 2022   
    Those who initially recover from COVID-19 may experience new-onset rheumatic conditions, worsening of previously diagnosed rheumatic conditions, or post-COVID syndrome. As we continue to learn more about the effects of COVID-19, the awareness of these manifestations will play a key role in the appropriate management of these patients.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Anti-inflammatory activity of PLA2 inhibitory Saccharumoside-B. (Pubmed Central) -  Oct 25, 2022   
    Saccharumoside-B showed significant PLA2 inhibition. It can become a potential lead molecule in synthesizing a new class of selective PLA2 inhibitors with a high safety profile in the future.
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Erythematous flexural eruption in a young man. (Pubmed Central) -  Oct 25, 2022   
    He had received topical corticosteroids, antifungals and oral prednisolone without improvement. Histopathological examination revealed confluent parakeratosis with retention of basophilic keratohyalin granules within the stratum corneum.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Clinical investigation of a unique type of hypothalamic adrenal insufficiency. (Pubmed Central) -  Oct 25, 2022   
    Moreover, more than half of the patients were fine after discontinuing hydrocortisone replacement therapy. These results indicate that this unique type of hypothalamic AI has a curable clinical course making hydrocortisone replacement therapy a novel therapeutic option.
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
    Journal:  Bilateral, sequential orbital inflammatory syndrome associated with ruxolitinib. (Pubmed Central) -  Oct 25, 2022   
    Although there are no previous documented cases of ruxolitinib associated orbital inflammatory syndrome, a similar JAK inhibitor medication, Fedratinib, has been reported to cause a similar side effect. We propose that her ruxolitinib paradoxically lead to a pro-inflammatory state leading to bilateral, sequential orbital inflammatory syndrome.
  • ||||||||||  Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Trial primary completion date, Minimal residual disease:  Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (clinicaltrials.gov) -  Oct 25, 2022   
    P2,  N=32, Recruiting, 
    Both formulations were well tolerated by all study participants. Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
    New trial:  A Study of YUTIQ (clinicaltrials.gov) -  Oct 25, 2022   
    P=N/A,  N=15, Recruiting, 
  • ||||||||||  HR20013 / Jiangsu Hengrui Pharma
    Enrollment open:  Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors (clinicaltrials.gov) -  Oct 25, 2022   
    P3,  N=752, Recruiting, 
    Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Jan 2024 --> Jul 2024 Not yet recruiting --> Recruiting
  • ||||||||||  dexamethasone / Generic mfg.
    TACKLING ADIPOSE TISSUE MACROPHAGE AS A NOVEL STRATEGY TO REDUCE LIVER FIBROSIS IN NAFLD () -  Oct 23, 2022 - Abstract #AASLD2022AASLD_872;    
    Selective modulation of ATM phenotype by chronic administration of Dextran-dexa conjugates attenuates liver inflammation and fibrosis. These results suggest that reducing the pro-inflammatory phenotype of ATMs might be a good strategy to reduce hepatic fibrosis and inflammation in NAFLD
  • ||||||||||  GEN-3026 / Gencia, Takeda
    HU6 REDUCES LIVER FAT IN SUBJECTS WITH HIGH BMI NAFLD: TOP-LINE RESULTS FROM A PHASE 2a TRIAL (Room 146) -  Oct 23, 2022 - Abstract #AASLD2022AASLD_468;    
    HU6 dosing was associated with significant improvements across primary and secondary endpoints important for NAFLD/NASH. The safety and tolerability of HU6 combined with the ability to reduce hepatic and whole-body adiposity and the enhanced treatment effect in subjects with and without elevated HbA1c suggest the potential to improve patient outcomes by improving NASH parameters and potentially reduce the progression to end stage liver disease.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Orencia (abatacept) / BMS
    Journal:  Treatment of severe COVID-19: an evolving paradigm. (Pubmed Central) -  Oct 23, 2022   
    The addition of a second immunomodulator, such as an interleukin-6 inhibitor or a Janus kinase inhibitor, has been associated with clinical benefit in a subset of patients with moderate-to-severe disease, but their use remains controversial. This manuscript reviews what is known about the approach to treatment of severe COVID-19 and examines how immunomodulators such as infliximab and abatacept may alter clinical management and COVID-19 research in the years ahead based on the results of randomized, controlled trials.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  A Guide to COVID-19 Antiviral Therapeutics: A Summary and Perspective of the Antiviral Weapons Against SARS-CoV-2 Infection. (Pubmed Central) -  Oct 22, 2022   
    Drugs that prevent the virus from replicating include: Paxlovid, remdesivir, molnupiravir, favipiravir, ribavirin, and Kaletra...Lastly, drugs that target immune response regulation include interferons and the use of anti-inflammatory drugs such as dexamethasone...Learning more about these therapies helps raise awareness to the general population about the options available to them to aid in the reduction of the severity of COVID-19 infection. In this 'A Guide To' article, we provide an in-depth insight into the development of antiviral therapeutics against SARS-CoV-2 and their ability to help fight COVID-19.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  Enhanced tendon healing by a tough hydrogel with an adhesive side and high drug-loading capacity. (Pubmed Central) -  Oct 22, 2022   
    The hydrogel is biocompatible, strongly adheres to patellar, supraspinatus and Achilles tendons of live rats, boosted healing and reduced scar formation in a rat model of Achilles-tendon rupture, and sustainably released the corticosteroid triamcinolone acetonide in a rat model of patellar tendon injury, reducing inflammation, modulating chemokine secretion, recruiting tendon stem and progenitor cells, and promoting macrophage polarization to the M2 phenotype. Hydrogels with 'Janus' surfaces and sustained-drug-release functionality could be designed for a range of biomedical applications.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Microfluidic Preparation of Gelatin Methacryloyl Microgels as Local Drug Delivery Vehicles for Hearing Loss Therapy. (Pubmed Central) -  Oct 22, 2022   
    Here, we developed dexamethasone sodium phosphate-encapsulated gelatin methacryloyl (Dexsp@GelMA) microgel particles, with finely tunable size through well-designed microfluidics, as otic drug delivery vehicles for hearing loss therapy...Moreover, the Dexsp@GelMA microgels, via intratympanic administration, could ameliorate acoustic noise-induced hearing loss and attenuate hair cell loss and synaptic ribbons damage more effectively than Dexsp alone. Our results strongly support the adhesive and intricate microfluidic-derived GelMA microgels as ideal intratympanic delivery vehicles for inner ear disease therapies, which provides new inspiration for microfluidics in drug delivery to the fine organs.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Could Endogenous Glucocorticoids Influence SARS-CoV-2 Infectivity? (Pubmed Central) -  Oct 22, 2022   
    Endogenous glucocorticoids and their synthetic analogues, such as dexamethasone, stimulate receptor-mediated signal transduction mechanisms on target cells...Further, glucocorticoids interactions with Spike could protect against a broad spectrum of coronaviruses and their variants that utilize Spike for infection of the host. These notions may be useful for the design of new antivirals for coronavirus diseases.